The Following is a Paid for Advertisement and not a solicitation or recommendation to buy or sell securities. Epicstockpicks.com
is not a licensed financial advisor and does its best to bring you accurate information but errors may and sometimes do occur.

Click here to view this message in your browser.
   
Home  |  Trading School   |   Facebook   |   Twitter   |   Disclaimer   |   Contact   |  Go VIP!

THE NEW EPIC MEDICAL MARJUANA PICK IS
PMCB (PharmaCyte Biotech, Inc)!


Hello Traders,

PMCB (PharmaCyte Biotech Inc) is our New Epic Pick!
Last Trade: .1624  |  SEC Filings  |  Latest News

Begin your research at http://www.pharmacytebiotech.com/


Are you ready to kick-start Medical Marjuana season?  As the sector begins to heat up this time of year - especially with Alaska, Washington DC, and Oregon joining Washington and Colorado to fully legalize recreational use, tonight we're bringing back a 3-TIME Winner which delivered up to 277% GAINS to members last year!

Some of you may remember a little ticker called NVLX - easily one of the hottest plays in the MJ sector last year.  Last week, the company had officially renamed to PharmaCyte Biotech Inc. and now trades under the ticker, PMCB.

PMCB is one of the few Biotech companies in the Medical Marjuana sector as it focuses on potentially ground-breaking applications for illnesses such as Cancer and Diabetes through it's cutting-edge "Live-Cell Encapsulation" Technology to which they claim world-wide exclusive rights. 

But what really has us excited is the company's research in Ca.nnabis with this "Cell-in-a-Box" technology!

Today, PMCB is now trading at historical support levels - cheaper than ever!  As the Sector begins to heat up - could this be another major "Ground Floor" situation?

Keep in mind, a few months ago, Wealthmakers.com, a respected Wall St. research firm, gave this a PRICE VALUATION OF $1.90!  That would be an astronomical 1000%+ GAIN from the current price!

Let's dig in...


PMCB - READY TO MAKE MOVES IN 2015?
There is no doubt that PMCB was one of our most successful profiles of all time.  As you can see, last year, we called the bottom as traders capitalized on a nearly 300% Rally to highs of .62!

Today PMCB is back at those very same "Pre-Breakout" levels from 2014!  Trading at this historical support level, could this be the staging point for another epic rally?




Let's see what PMCB has been up to...


PMCB - THE NEXT BREAKTHROUGH BIOTECH IN CANCER TREATMENT?
PharmaCyte Biotech (PMCB) is an international clinical stage biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cell technology known as Cell-in-a-Box(R). The company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of medical marjuana for oncology applications.

So how does Cell-in-a-Box Encapsulation work?
This technology employed by PMCB is a way to enclose living cells in a protective "cocoon" about the size of the head of a pin - holding appx. 10,00 cells.  This technology can be classified as a “platform” upon which treatments for different indications may be built.

Because the capsules that enclose cells are made of cellulose, they are very robust, do not degrade, and can withstand various external forces and this allows them to be implanted using needles or catheters without damage.

Combatting Diabetes, Pancreatic & Breast Cancer
PMCB's pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and widely used anticancer drug ifosfamide (IFEX®). Ifosfamide is a prodrug that must be activated to its "cancer-killing" form for it to be effective; this usually occurs in the liver.  [Read more HERE]

These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Call it "targeted chemotherapy" - which has proven remarkably effective in past clinical trials.

The American Cancer Society estimates that in the U.S. alone, 45,220 new cases of pancreatic cancer will be diagnosed in 2013 and 38,460 deaths will be attributable to the dreaded disease this year.

PMCB is currently preparing for future Phase 2b clinical trials with the hopes of also gaining FDA approval of their unique live-cell encapsulation-based treatment for advanced, inoperable pancreatic cancer.


IN MAJOR RECENT NEWS: PMCB announced they have received "orphan drug" designation from the U.S. Food and Drug Administration (FDA) for the Company's pancreatic cancer treatment, with applications filed with the EMA and the TGA for the same status in Europe and Australia!

PMCB also announced key partnerships with Fisher BioServices and Inno Biologics to generate cell clones which are essential to the company's Phase III Trials for encapsulating cells for pancreatic cancer treatments.  How big is this news?  So big that PMCB was featured in a recent FORBES Article highlighting this partnership!


PMCB BELIEVES CANNAB.IS CAN TREAT CANCER VIA CELL-IN-A-BOX
This is one diverse BioTech company!  PMCB is truly taking the idea of "Medical Mariju.ana" to the next level.  Through their subsidiary, Medical Marjuana Sciences, Inc., they believe utilizing cannabinoids from Cannab.is is an effective treatment for some of the deadliest forms of cancer.

The company first announced breaking news regarding a New Study validating their approach.  PMCB has stated that its subsidiary will attempt to use the "Cell-in-a-Box" encapsulation technology in its medical marjuana research to develop treatments for some of the most hard-to-treat cancers.

PMCB is currently waiting on a Schedule 1 license from the DEA in order to conduct research using marijuana.


THE BOTTOM LINE
It's Medical Marjuana season!  After a Landmark year in 2014 with New US States legalizing for both recreational and medical use and for the first time *ever* - a new poll indicating that a majority of Americans now favor legalization, could 2015 be even bigger?

Like last year, PMCB remains one of the stand-outs in the Sector due to it's Biotech technology.  This company is MORE than just a "Medical Marjuana" stock.

Now, cheaper than ever, trading at historical support levels - could this be the "Ground Floor" staging point for another rally this year?

Needless to say, like last year we'll be sticking with this for a while!  Make sure you have PMCB on your screen Tomorrow Morning and Follow on Twitter for Updates + Play-by-Play!


Good Trading,
Epicstockpicks.com
 

          
 
GO VIP for a Limted Time Only!  Read More...
 
Please read our Full Disclaimer:  http://www.epicstockpicks.com/disclaimer

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: Epicstockpicks.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. EPICSTOCKPICKS.COM WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at EPICSTOCKPICKS.COM &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe here.

Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Gains mentioned in our newsletter and on our website may be based on End of Day or intraday data. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at http://www.epicstockpicks.com/disclaimer

We encourage all to read the SEC's INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold Epicstockpicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Epicstockpicks.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Epicstockpicks.com or an offer or solicitation to buy or sell any security. 

COMPENSATION: Epicstockpicks.com has been compensated twenty-thousand dollars cash via bank wire by a third party, Cream Consulting Group, Inc. for a one day PharmaCyte Biotech Inc. advertising services contract.  Epicstockpicks.com does not own any shares of PMCB. Epicstockpicks.com does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Epicstockpicks.com may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Epicstockpicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is collected from public sources only such as the profiled company's website, news releases, and corporate filings, but has not been verified in any way to ensure the publicly available information is correct. Epicstockpicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, Epicstockpicks.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Epicstockpicks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Epicstockpicks.com is compliant with the Can Spam Act of 2003. Epicstockpicks.com does not offer such advice or analysis, and Epicstockpicks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.  Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, Epicstockpicks.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. Epicstockpicks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Epicstockpicks.com is not responsible for any claims made by the companies advertised herein, nor is Epicstockpicks.com responsible for any other promotional firm, its program or its structure.